Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)
Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)
复制标题
DOI：
10.1093/infdis/jis269
复制
发表时间：
2012-06-01
影响因子：
6.4
通讯作者：
Bishai, William R.
中科院分区：
文献类型：
--
作者：
Maiga, Mamoudou;Lun, Shichun;Bishai, William R.
潜伏性结核感染（LTBI）的个体存在再激活的风险，并且慢性炎症性疾病的几种治疗与这种再激活高度相关。一种新的Janus激酶抑制剂，托法替尼（CP-690550），已显示出治疗炎症性疾病的有希望的结果，从而提高了对活动性结核病风险的关注。我们的目标是使用小鼠结核病模型来表征托法替尼对LTBI的影响。我们的数据表明，托法替尼减少结核分枝杆菌的宿主遏制，促进肺部细菌复制，表明结核病复发。托法替尼可能对人体中LTBI再激活具有显著风险。
Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.